Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Assets: 2012-2024

Historic Non-Current Assets for RedHill Biopharma (RDHL) over the last 12 years, with Dec 2024 value amounting to $6.1 million.

  • RedHill Biopharma's Non-Current Assets fell 7.93% to $5.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.8 million, marking a year-over-year decrease of 7.93%. This contributed to the annual value of $6.1 million for FY2024, which is 11.22% down from last year.
  • Latest data reveals that RedHill Biopharma reported Non-Current Assets of $6.1 million as of FY2024, which was down 11.22% from $6.9 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Non-Current Assets ranged from a high of $109.7 million in FY2020 and a low of $6.1 million during FY2024.
  • Over the past 3 years, RedHill Biopharma's median Non-Current Assets value was $6.9 million (recorded in 2023), while the average stood at $28.7 million.
  • Per our database at Business Quant, RedHill Biopharma's Non-Current Assets skyrocketed by 425.48% in 2020 and then slumped by 90.53% in 2023.
  • Over the past 5 years, RedHill Biopharma's Non-Current Assets (Yearly) stood at $109.7 million in 2020, then declined by 16.14% to $92.0 million in 2021, then decreased by 20.72% to $73.0 million in 2022, then plummeted by 90.53% to $6.9 million in 2023, then fell by 11.22% to $6.1 million in 2024.